
    
      This is a phase II , openlabel, randomized study in patients with confirmed diagnosis of
      potentially or borderline resectable metastatic colorectal adenocarcinoma (RAS and B-RAF WT
      tumors ), who have not received prior chemotherapy for their metastatic disease.

      The study is designed to compare pathological responses observed after pre-operative
      chemotherapy cetuximab with FOLFOX or FOLFIRI.
    
  